NDAORALSOLUTION
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
THYQUIDITY (levothyroxine sodium) by Pfizer is synthesis. Approved for hypothyroidism, congenital hypothyroidism. First approved in 2020.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYQUIDITY is a liquid oral formulation of levothyroxine sodium approved by Pfizer in November 2020 for treating hypothyroidism and congenital hypothyroidism. The drug works by replacing deficient thyroid hormones, with T4 converting to the active T3 form in peripheral tissues to regulate cellular metabolism and gene transcription. This solution formulation addresses bioavailability challenges in patients with absorption difficulties.
$0.054MPart D
Peak5.3 years to LOEEarly-stage peak lifecycle product with minimal current market penetration; commercial opportunity exists but requires significant market share capture against entrenched competitors.
Mechanism of Action
synthesis. Triiodothyronine (T 3 ) and levothyroxine (T 4 ) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of…
Indications (2)
Worked on THYQUIDITY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.